Premium
Phase II trial of prednimustine, L‐1031, (NSC‐134087) in advanced breast cancer
Author(s) -
Mouridsen H. T.,
Kristensen D.,
Nielsen J. Halskov,
Dombernowsky P.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19800715)46:2<253::aid-cncr2820460205>3.0.co;2-1
Subject(s) - medicine , endocrine system , breast cancer , chemotherapy , oncology , cancer , gastroenterology , hormone
The therapeutic effect of prednimustine was studied in 35 patients with advanced breast cancer resistant to previous cytotoxic and/or endocrine therapy. Response (PR + CR) was obtained in 14 patients (40%) of a median duration of five months. Among the 14 responding patients, 10 were resistant to previous endocrine therapy and chemotherapy, in all cases including alkylating agents, and 4 were resistant to previous endocrine therapy. Hematologic toxicity was rather pronounced, but other toxicities were only moderate.